SCHEMBL6190025

SCHEMBL6190025

Fc1cccc2ccn(Cc3ccc(Cl)cc3)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.52
MAPT P10636 2/20 0.45
THRB P10828 1/20 0.45
APP P05067 2/20 0.41
HTR6 P50406 1/20 0.41
VEGFA P15692 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
MAOB P27338 1/20 0.39
CYP19A1 P11511 1/20 0.39
KMT2A Q03164 2/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
CCR2 P41597 1/20 0.39
LMNA P02545 2/20 0.38
DBH P09172 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
SNCA P37840 1/20 0.38
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085911 0.81 ADRA2A (0.50) KCNA3MAPTTHRBAPPHTR6
SCHEMBL6085455 0.78 BACE1 (0.47) KCNA3MAPTTHRBAPPHTR6
SCHEMBL6086348 0.77 KCNA3 (0.43) KCNA3MAPTTHRBAPPCYP19A1
SCHEMBL987890 0.76 PTGER4 (0.51) MAPTAPPVEGFAEGLN1POLB
SCHEMBL6087453 0.75 RECQL (0.49) MAPTVEGFAEGLN1KMT2ATP53
SCHEMBL12583982 0.75 MAPT (0.43) KCNA3MAPTTHRBVEGFAEGLN1
SCHEMBL6086946 0.74 HTR2A (0.51) KCNA3MAPTTHRBAPPHTR6
SCHEMBL12383523 0.74 CYP19A1 (0.45) CYP19A1
SCHEMBL6085685 0.73 ADRA2A (0.49) MAPTTHRBAPPHTR6CYP19A1
SCHEMBL5461428 0.73 MAPK14 (0.51) MAPTAPPKMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244652-B1 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY CELL THERAPEUTICS EUROPE SRL (IT) 2005-08-24 EP disclosed
US-6753342-B2 ANTICARCINOGENIC AGENTS FOR LUNG AND COLON CANCER TREATMENT NOVUSPHARMA S.P.A. (IT) 2004-06-22 US disclosed
US-20030158153-A1 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung NOVUSPHARMA S.P.A. (IT) 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158153-A1 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung IDO2, IDO1, TXNRD2 KCNA3 3460/4885MAPT 4761/4885THRB 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.